Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BILN 2061 in Cirrhosis and Chronic Hepatitis C
NCT02226939Phase 2Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Sep 2002
- Primary completion
- Nov 2002
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, double-blind trial in hepatitis C virus infection comparing BILN 2061 ZW with Placebo (2 arms). Primary endpoint: Virus load (VL) as determined by number of copies of HCV mRNA per ml serum at 14 days. Started Sep 2002; status: completed.
02
Drugs
ciluprevir
03
Conditions
hepatitis C virus infection
Beyond the preview
Go deeper on NCT02226939.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02226939.